| 14.68 0.83 (5.99%) | 10-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.41 | 1-year : | 20.15 |
| Resists | First : | 15.76 | Second : | 17.26 |
| Pivot price | 14.55  |
|||
| Supports | First : | 13.34 | Second : | 11.09 |
| MAs | MA(5) : | 13.94 |
MA(20) : | 14.75 |
| MA(100) : | 14.47 |
MA(250) : | 16.51 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 17.9 |
D(3) : | 12.3 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 22.55 | Low : | 11.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SIBN ] has closed below upper band by 46.2%. Bollinger Bands are 14.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.71 - 14.77 | 14.77 - 14.84 |
| Low: | 13.76 - 13.82 | 13.82 - 13.89 |
| Close: | 14.57 - 14.66 | 14.66 - 14.78 |
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Sun, 06 Oct 2024
Anthony J. Recupero Sells 3,305 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock - MarketBeat
Fri, 04 Oct 2024
SI-BONE, Inc. (NASDAQ:SIBN) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Fri, 04 Oct 2024
SI-BONE, Inc. (NASDAQ:SIBN) Shares Purchased by Marshall Wace LLP - MarketBeat
Mon, 30 Sep 2024
SI-BONE Inc (SIBN) Shares Up 4.78% on Sep 30 - GuruFocus.com
Wed, 25 Sep 2024
Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt? - Simply Wall St
Mon, 26 Aug 2024
SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 42 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 99.6 (%) |
| Shares Short | 1,650 (K) |
| Shares Short P.Month | 1,560 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.97 |
| Profit Margin | -27.2 % |
| Operating Margin | -25.3 % |
| Return on Assets (ttm) | -12.6 % |
| Return on Equity (ttm) | -23.9 % |
| Qtrly Rev. Growth | 20 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.61 |
| EBITDA (p.s.) | -0.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -14.69 |
| PEG Ratio | -1.8 |
| Price to Book value | 3.69 |
| Price to Sales | 4.06 |
| Price to Cash Flow | -33.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|